Status:
TERMINATED
Pharmacokinetics of Intranasal Ketorolac in Children
Lead Sponsor:
Columbia University
Conditions:
Evaluating Pharmacokinetics of Intranasal Ketorolac
Pain
Eligibility:
All Genders
8-17 years
Phase:
PHASE1
Brief Summary
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that is typically given to both adults and children by the intravenous (IV) or intramuscular (IM) route for analgesic purposes. Ketorolac ca...
Detailed Description
The intranasal (IN) route of administering medications is an effective means of delivering analgesics to children in a painless and minimally distressing manner, especially in comparison to traditiona...
Eligibility Criteria
Inclusion
- Present to the emergency department with a painful condition for which the treating physician decides to administer ketorolac as part of their usual care.
Exclusion
- Known allergy to ketorolac
- Contraindication to receiving ketorolac
- Receiving any NSAID within the past 6 hours
- Presence of an intranasal obstruction that cannot be readily cleared using suction or nose-blowing
- Inability to speak English or Spanish
- Critical illness
Key Trial Info
Start Date :
February 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 29 2017
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT02297906
Start Date
February 1 2015
End Date
November 29 2017
Last Update
January 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York Presbyterian Morgan Stanley Children's Hospital
New York, New York, United States, 10032